TY - JOUR
T1 - Genome-wide association study of blood pressure and hypertension
AU - Levy, Daniel
AU - Ehret, Georg B.
AU - Rice, Kenneth
AU - Verwoert, Germaine C.
AU - Launer, Lenore J.
AU - Dehghan, Abbas
AU - Glazer, Nicole L.
AU - Morrison, Alanna C.
AU - Johnson, Andrew D.
AU - Aspelund, Thor
AU - Aulchenko, Yurii
AU - Lumley, Thomas
AU - Köttgen, Anna
AU - Vasan, Ramachandran S.
AU - Rivadeneira, Fernando
AU - Eiriksdottir, Gudny
AU - Guo, Xiuqing
AU - Arking, Dan E.
AU - Mitchell, Gary F.
AU - Mattace-Raso, Francesco U.S.
AU - Smith, Albert V.
AU - Taylor, Kent
AU - Scharpf, Robert B.
AU - Hwang, Shih Jen
AU - Sijbrands, Eric J.G.
AU - Bis, Joshua
AU - Harris, Tamara B.
AU - Ganesh, Santhi K.
AU - O'Donnell, Christopher J.
AU - Hofman, Albert
AU - Rotter, Jerome I.
AU - Coresh, Josef
AU - Benjamin, Emelia J.
AU - Uitterlinden, André G.
AU - Heiss, Gerardo
AU - Fox, Caroline S.
AU - Witteman, Jacqueline C.M.
AU - Boerwinkle, Eric
AU - Wang, Thomas J.
AU - Gudnason, Vilmundur
AU - Larson, Martin G.
AU - Chakravarti, Aravinda
AU - Psaty, Bruce M.
AU - Van Duijn, Cornelia M.
N1 - Funding Information:
The authors acknowledge the essential role of the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) Consortium in development and support of this manuscript. CHARGE members include The Netherland’s Rotterdam Study (RS), Framingham Heart Study (FHS), Cardiovascular Health Study (CHS), the NHLBI’s Atherosclerosis Risk in Communities (ARIC) Study, and the NIA’s Iceland Age, Gene/Environment Susceptibility (AGES) Study. AGES: The Age, Gene/Environment Susceptibility Reykjavik Study is funded by NIH contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association) and the Althingi (the Icelandic Parliament). ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021 and N01-HC-55022, and grants R01HL087641, R01HL59367, R37HL051021, R01HL086694 and U10HL054512; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. A.K. is supported by a German Research Foundation Fellowship. CHS: The Cardiovascular Health Study was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant numbers U01 HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute. A full list of principal CHS investigators and institutions can be found at http://www. chs-nhlbi.org/pi.htm. FHS: The National Heart, Lung, and Blood Institute’s Framingham Heart Study is a joint project of the National Institutes of Health and Boston University School of Medicine and was supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (contract No. N01-HC-25195) and its contract with Affymetrix, Inc. for genotyping services (contract No. N02-HL-6-4278). Analyses reflect the efforts and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. RS: The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); The Netherlands Heart Foundation; the Ministry of Education, Culture and Science; the Ministry of Health Welfare and Sports; the European Commission (DG XII); the Municipality of Rotterdam and the ErasmusMC translational research fund (2004-44). Support for genotyping was provided by the Netherlands Organization for Scientific Research (NWO Groot, 175.010.2005.011, 911.03.012) and Research Institute for Diseases in the Elderly (014.93.015; RIDE2). This study was supported by the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank P. Arp, M. Jhamai, M. Moorhouse, M. Verkerk and S. Bervoets for their help in creating the database and M. Struchalin for his contributions to the imputations of the data. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practioners and pharmacists.
PY - 2009/6
Y1 - 2009/6
N2 - Blood pressure is a major cardiovascular disease risk factor. To date, few variants associated with interindividual blood pressure variation have been identified and replicated. Here we report results of a genome-wide association study of systolic (SBP) and diastolic (DBP) blood pressure and hypertension in the CHARGE Consortium (n = 29,136), identifying 13 SNPs for SBP, 20 for DBP and 10 for hypertension at P 4 × 10 7. The top ten loci for SBP and DBP were incorporated into a risk score; mean BP and prevalence of hypertension increased in relation to the number of risk alleles carried. When ten CHARGE SNPs for each trait were included in a joint meta-analysis with the Global BPgen Consortium (n = 34,433), four CHARGE loci attained genome-wide significance (P 5 × 10 8) for SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), six for DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4) and one for hypertension (ATP2B1). Identifying genes associated with blood pressure advances our understanding of blood pressure regulation and highlights potential drug targets for the prevention or treatment of hypertension.
AB - Blood pressure is a major cardiovascular disease risk factor. To date, few variants associated with interindividual blood pressure variation have been identified and replicated. Here we report results of a genome-wide association study of systolic (SBP) and diastolic (DBP) blood pressure and hypertension in the CHARGE Consortium (n = 29,136), identifying 13 SNPs for SBP, 20 for DBP and 10 for hypertension at P 4 × 10 7. The top ten loci for SBP and DBP were incorporated into a risk score; mean BP and prevalence of hypertension increased in relation to the number of risk alleles carried. When ten CHARGE SNPs for each trait were included in a joint meta-analysis with the Global BPgen Consortium (n = 34,433), four CHARGE loci attained genome-wide significance (P 5 × 10 8) for SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), six for DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4) and one for hypertension (ATP2B1). Identifying genes associated with blood pressure advances our understanding of blood pressure regulation and highlights potential drug targets for the prevention or treatment of hypertension.
UR - http://www.scopus.com/inward/record.url?scp=67349208839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349208839&partnerID=8YFLogxK
U2 - 10.1038/ng.384
DO - 10.1038/ng.384
M3 - Article
C2 - 19430479
AN - SCOPUS:67349208839
SN - 1061-4036
VL - 41
SP - 677
EP - 687
JO - Nature genetics
JF - Nature genetics
IS - 6
ER -